Advertisement

Ads Placeholder
Loading...

IntegraGen SA

ALINT.PAEURONEXT
Healthcare
Biotechnology
0.19
0.001(0.53%)
U.S. Market opens in 55h 44m

IntegraGen SA Fundamental Analysis

IntegraGen SA (ALINT.PA) shows weak financial fundamentals with a PE ratio of -0.80, profit margin of -23.22%, and ROE of -1.48%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position138.54%
PEG Ratio0.00

Areas of Concern

ROE-1.48%
Operating Margin-28.57%
We analyze ALINT.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -189.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-189.7/100

We analyze ALINT.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALINT.PA struggles to generate sufficient returns from assets.

ROA > 10%
-42.96%

Valuation Score

Excellent

ALINT.PA trades at attractive valuation levels.

PE < 25
-0.80
PEG Ratio < 2
0.00

Growth Score

Weak

ALINT.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

ALINT.PA shows balanced financial health with some risks.

Debt/Equity < 1
1.23
Current Ratio > 1
1.19

Profitability Score

Weak

ALINT.PA struggles to sustain strong margins.

ROE > 15%
-147.87%
Net Margin ≥ 15%
-23.22%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALINT.PA Expensive or Cheap?

P/E Ratio

ALINT.PA trades at -0.80 times earnings. This suggests potential undervaluation.

-0.80

PEG Ratio

When adjusting for growth, ALINT.PA's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values IntegraGen SA at 3.67 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.67

EV/EBITDA

Enterprise value stands at -0.78 times EBITDA. This is generally considered low.

-0.78

How Well Does ALINT.PA Make Money?

Net Profit Margin

For every $100 in sales, IntegraGen SA keeps $-23.22 as profit after all expenses.

-23.22%

Operating Margin

Core operations generate -28.57 in profit for every $100 in revenue, before interest and taxes.

-28.57%

ROE

Management delivers $-1.48 in profit for every $100 of shareholder equity.

-1.48%

ROA

IntegraGen SA generates $-42.96 in profit for every $100 in assets, demonstrating efficient asset deployment.

-42.96%

Following the Money - Real Cash Generation

Operating Cash Flow

IntegraGen SA generates limited operating cash flow of $-645.51K, signaling weaker underlying cash strength.

$-645.51K

Free Cash Flow

IntegraGen SA generates weak or negative free cash flow of $-646.23K, restricting financial flexibility.

$-646.23K

FCF Per Share

Each share generates $-0.10 in free cash annually.

$-0.10

FCF Yield

ALINT.PA converts -52.03% of its market value into free cash.

-52.03%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.80

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.002

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.67

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.19

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.23

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.19

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.48

vs 25 benchmark

ROA

Return on assets percentage

-0.43

vs 25 benchmark

ROCE

Return on capital employed

-2.49

vs 25 benchmark

How ALINT.PA Stacks Against Its Sector Peers

MetricALINT.PA ValueSector AveragePerformance
P/E Ratio-0.8028.45 Better (Cheaper)
ROE-147.87%763.00% Weak
Net Margin-23.22%-45265.00% (disorted) Weak
Debt/Equity1.230.34 Weak (High Leverage)
Current Ratio1.192795.60 Neutral
ROA-42.96%-16588.00% (disorted) Weak

ALINT.PA outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews IntegraGen SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ